GroomDoom
437 views
Rate Now: 1 2 3 4

average rating: 0.00 / 0 ratings
Created by samuelgroom
DESCRIPTION:

Date updated:07-11-2007

small stocks that appear dead, and most likely are.

symbol name last price % change open
  • +
  • PPMD.PK
    Protide Pharmaceu
  • $0.035
  • 0.00%
  • $N/A

stem cell transport and storage solution company. http://www.nsf.gov/pubs/2004/nsf0450/activities.htm Profitable company 4,000,000 shares outstanding Recent move to Chicago area from Minnesota.

People owning PPMD.PK also tend to own: AGIXCYTX

TheStreet.com Rating: No Rating What is this?

  • +
  • AGIX
    Agix
  • $0.00
  • N/A
  • $N/A

severely beaten down in the cardiovascular arena. now trying to come back as a diabetes preventing medicine. with recent black box warning for the tzd's, may have a chance. Several dual application drugs looking for approval-both lipid lowering relatives looking for diabetes approval New drug may soon help type 2 diabetics NEW ORLEANS, July 9 (UPI) -- A U.S. study suggests people with type 2 diabetes might soon be able to control both their glucose and cholesterol levels with a single drug. Researchers led by Professor Vivian Fonseca at Tulane University conducted a clinical trial that demonstrated the compound colesevelam HCl, in combination with Sulfonylurea-based therapy in patients with inadequately controlled type 2 diabetes, achieved significantly reduced glucose levels versus those in the study taking a placebo. "People with uncontrolled type 2 diabetes and high cholesterol face a number of challenges in keeping their glucose levels and cholesterol in check," said Fonseca. "This study demonstrated the potential to improve two important metabolic parameters with one drug." Patients who received colesevelam HCl were shown to have significant reductions in blood sugar levels, and participants' lipid profiles in the colesevelam HCl group also showed substantial improvement over placebo. An application for the commercial production and sale of the drug is pending with the U.S. Food and Drug Administration.

People owning AGIX also tend to own: ABPIACADAVGNCOLYDEPOMNTANABI

TheStreet.com Rating: No Rating What is this?

  • +
  • CYTX
    Cytori Therapeuti
  • $5.88
  • +0.51%
  • $5.97

stem cell harvesting and noon-hour plastic surgery company Women in Europe could be having boob jobs on their lunch breaks as early as next year, according to a scientific journal. A fast-track breast enlargement process is to be rolled out by a Californian biotech company and could be introduced across Europe by next year, the Chemistry and Industry magazine says. The procedure, called Celution, takes just over an hour and involves injecting a "super-charged'' fat mixture into breast tissue. Fat is taken from a patient's buttocks or stomach using minor liposuction under local anaesthetic. The useful stem cells are separated out and an hour later a dose of stem and regenerative cells is packaged into a cartridge ready for injection. It costs a few thousand dollars and the breasts enlarge over about six months, according to the program's creator Cytori Therapeutics. Cytori Therapeutics head of research and development Kai Pinkernel said the company's initial focus will be on reconstructive surgery in breast cancer patients. (from Fox News 7/11/2007) http://medgadget.com/archives/2006/02/the_celution_sy.html

People owning CYTX also tend to own: ABPATICMGICVAFRPTKYPHMER

TheStreet.com Rating: E+ What is this?

 

Start Price

Return Value

Start Date

PPMD.PK 0.15 ------ Jul 8th
AGIX 2.10 ------ Jul 8th
CYTX 5.93 -0.84% Jul 11th

Average return:

-0.84%

Success rate:

0%

Tracking Started: 07-08-2007

Comments not available

ADD YOUR COMMENTS:

Dividend Stocks for the Week

By Jonas Elmerraji Posted on Dec. 1, 2009 After an earnings season that has brought a significant stream of dividend-increasers, stocks are taking a step back, with jus...

12.01.09 | 13:52 PM
This Week's 'Barron's' Roundup

By Roberto Pedone Posted on Dec. 1, 2009 Bullish and Bearish: Each week, Barron’s publishes bullish and bearish stories on a variety of stocks. We present summaries o...

12.01.09 | 12:23 PM
Cramer's Take on Headline Stocks...

Posted on Dec. 1, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is to gather as much in...

12.01.09 | 11:45 AM
Rocket Stocks for the Week

By Jonas Elmerraji Posted on Nov. 30, 2009 With Black Friday behind us and another data-heavy week ahead, it’s time to turn once again to Rocket Stocks, our list of b...

11.30.09 | 09:16 AM
more articles
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
Nymph's Trading Daily Trading Diary
04.13.09 | 01:10 AM From author Trading Nymph
Options-Selling Short
12.01.09 | 06:48 AM From author Knocka
more forums
today 's lists
Stocks With Unusual Option Activity

Unusually active options can often indicate that a major event in a stock is about to take place, or that unsophisticated investors (using options in lieu of leverage) are ... more

52-Week Highs

Here are some of the biggest stocks that made the 52-week high list on Dec. 1, 2009. more

TheStreet.com TV Videos

These are some of the stocks mentioned on TheStreet.com TV recently. Click the URL below each stock to watch the videos. more